RxDoctor Payments Data

Lorenzo Bortolotti, MD

Internal Medicine · Baytown, TXNPI 1215976238

Payments from drug & device makers

$544in general payments, 2019–2025

Across 28 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$86
  • AbbVie$62
  • Novo Nordisk$51
  • Idorsia Pharmaceuticals US Inc$48
  • Takeda Pharmaceuticals U.S.A., Inc.$43
  • Smith+Nephew$36
  • plus $218 from 11 others

What the payments were for

  • Food & beverage$544100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$544 in reported general payments places this provider in the 60th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$49,842
Medicare patients
154
Services billed
1,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide138$153,823
EliquisApixaban87$115,333
JardianceEmpagliflozin73$113,628
MounjaroTirzepatide72$92,111
JanuviaSitagliptin Phosphate69$87,028
TradjentaLinagliptin82$85,322
FarxigaDapagliflozin Propanediol40$55,038
XareltoRivaroxaban33$38,342
TrulicityDulaglutide18$27,792
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$24,040
Rosuvastatin Calcium650$18,687
Synjardy XrEmpagliflozin/Metformin Hcl13$15,797
MyrbetriqMirabegron16$14,735
Janumet XrSitagliptin Phos/Metformin Hcl12$12,985
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$7,880

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$51$153,823138 claims
AstraZenecaFarxiga, Breztri Aerosphere$18$62,91853 claims
GSKTrelegy Ellipta$16$24,04027 claims
Astellas Pharma US IncMyrbetriq$26$14,73516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Baytown

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →